I whole heartily disagree. There is significant patient risk when it comes to bad testing information. Women may attempt to elect to get invasive procedures (such as double mastectomy) based on their perceived BRCA status. This may lead to the rare infection and potential death, not including the emotional and physical suffering. And as the article alluded to, 23 and Me did "cross the line" when it started reporting warfarin related variants, when the science wasn't well understood [1].
Americans have already agreed that when it comes to healthcare markets, more rather than less regulation is necessary for making clairvoyant decisions (ie Federal Food, Drug, and Cosmetic Act which created the modern FDA). I think there is clearly potential for policy reform, but the complete lazzie-faire economic model just simply doesn't apply to the healtcare market.
Americans have already agreed that when it comes to healthcare markets, more rather than less regulation is necessary for making clairvoyant decisions (ie Federal Food, Drug, and Cosmetic Act which created the modern FDA). I think there is clearly potential for policy reform, but the complete lazzie-faire economic model just simply doesn't apply to the healtcare market.
[1]. https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/...